[go: up one dir, main page]

BRPI0815567B8 - anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica - Google Patents

anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica

Info

Publication number
BRPI0815567B8
BRPI0815567B8 BRPI0815567A BRPI0815567A BRPI0815567B8 BR PI0815567 B8 BRPI0815567 B8 BR PI0815567B8 BR PI0815567 A BRPI0815567 A BR PI0815567A BR PI0815567 A BRPI0815567 A BR PI0815567A BR PI0815567 B8 BRPI0815567 B8 BR PI0815567B8
Authority
BR
Brazil
Prior art keywords
integrin
alpha
antibodies
pharmaceutical composition
fusion protein
Prior art date
Application number
BRPI0815567A
Other languages
English (en)
Inventor
Hahn Diane
Mitjans Francesc
Adan Jaume
Lo Kin-Ming
Goodman Simon
Original Assignee
Merck Patent Gessellschaft Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gessellschaft Mit Beschraenkter Haftung filed Critical Merck Patent Gessellschaft Mit Beschraenkter Haftung
Publication of BRPI0815567A2 publication Critical patent/BRPI0815567A2/pt
Publication of BRPI0815567B1 publication Critical patent/BRPI0815567B1/pt
Publication of BRPI0815567B8 publication Critical patent/BRPI0815567B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos híbridos anti-alfa v-integrina projetados. a presente invenção se refere a anticorpos projetados que se ligam especificamente a receptores integrinas, especialmente à subunidade de receptor alfa v integrina. os anticorpos compreendem os locais de ligação de antígeno (c-drs) de um anticorpo anti-integrina de camundongo conhecido, bem como sequências variáveis de cadeia leve híbrida, sequências variáveis de cadeia pesada mutacionada (frs) e sequências constantes de cadeia pesada modificadas. os novos anticorpos têm propriedades imunogênicas e de expressão aperfeiçoadas e induzem excelente atividades antiangiogênico bem como atividades antitumor em humanos em monoterapia, mas também, e acima de tudo, em combinação com outros agentes de inibição de angiogênese e de tumor.
BRPI0815567A 2007-07-17 2008-07-17 anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica BRPI0815567B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07013964 2007-07-17
EP07013964.7 2007-07-17
PCT/EP2008/005852 WO2009010290A2 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies

Publications (3)

Publication Number Publication Date
BRPI0815567A2 BRPI0815567A2 (pt) 2015-02-18
BRPI0815567B1 BRPI0815567B1 (pt) 2019-06-04
BRPI0815567B8 true BRPI0815567B8 (pt) 2021-05-25

Family

ID=40029330

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815567A BRPI0815567B8 (pt) 2007-07-17 2008-07-17 anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica

Country Status (19)

Country Link
US (1) US8562986B2 (pt)
EP (2) EP2526967A1 (pt)
JP (1) JP5341889B2 (pt)
KR (1) KR101559596B1 (pt)
CN (1) CN101687039B (pt)
AU (1) AU2008277907B2 (pt)
BR (1) BRPI0815567B8 (pt)
CA (1) CA2693863C (pt)
CY (1) CY1113493T1 (pt)
DK (1) DK2167128T3 (pt)
EA (1) EA019485B1 (pt)
ES (1) ES2395799T3 (pt)
HR (1) HRP20120949T1 (pt)
IL (1) IL203269A (pt)
PL (1) PL2167128T3 (pt)
PT (1) PT2167128E (pt)
SI (1) SI2167128T1 (pt)
WO (1) WO2009010290A2 (pt)
ZA (1) ZA201001124B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747937C (en) 2008-12-23 2019-02-26 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
AU2010285265B2 (en) 2009-08-19 2015-05-21 Merck Patent Gmbh Antibodies for the detection of integrin complexes in FFPE material
SG192667A1 (en) * 2011-02-11 2013-09-30 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
WO2015035215A1 (en) * 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
KR20170052690A (ko) 2014-09-17 2017-05-12 메르크 파텐트 게엠베하 고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법
WO2016041616A1 (en) 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
BR112018010337A2 (pt) * 2015-11-23 2018-12-04 Merck Patent Gmbh anticorpo anti-alfa-v integrina para o tratamento de fibrose e/ou transtornos fibróticos
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
TW201834710A (zh) 2016-12-14 2018-10-01 美商寶珍那提公司 以整合素抑制劑治療胃腸道疾病
WO2018141894A1 (en) 2017-02-02 2018-08-09 Merck Patent Gmbh Preferred pairing of antibody domains
CN108948206B (zh) * 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
EP3692060A1 (en) 2017-10-03 2020-08-12 Merck Patent GmbH Cysteine engineered antigen-binding molecules
US11339221B2 (en) * 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
TW202027789A (zh) 2018-10-19 2020-08-01 德商馬克專利公司 用於治療大腸直腸癌之阿比特珠單抗(abituzumab)
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114366749B (zh) * 2020-10-15 2023-06-30 中国人民解放军海军军医大学 整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
SI0719859T1 (en) 1994-12-20 2003-12-31 Merck Patent Gmbh Anti-alpha V-integrin monoclonal antibody
JP3461945B2 (ja) 1994-12-26 2003-10-27 株式会社日本製鋼所 高低圧一体型タービンロータの製造方法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
KR20110140143A (ko) 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
PT1966245E (pt) * 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
US7669429B2 (en) 2006-01-19 2010-03-02 Bassler Sr G Scott Rapid food chiller

Also Published As

Publication number Publication date
JP2010533480A (ja) 2010-10-28
AU2008277907B2 (en) 2013-08-22
HRP20120949T1 (en) 2012-12-31
ZA201001124B (en) 2010-11-24
US8562986B2 (en) 2013-10-22
AU2008277907A1 (en) 2009-01-22
EA201070150A1 (ru) 2010-08-30
CA2693863C (en) 2017-10-03
IL203269A (en) 2014-11-30
CN101687039B (zh) 2014-04-16
PT2167128E (pt) 2013-01-24
KR101559596B1 (ko) 2015-10-12
WO2009010290A2 (en) 2009-01-22
WO2009010290A3 (en) 2009-04-09
KR20100057010A (ko) 2010-05-28
CN101687039A (zh) 2010-03-31
BRPI0815567B1 (pt) 2019-06-04
EP2167128B1 (en) 2012-10-24
DK2167128T3 (da) 2012-12-03
CY1113493T1 (el) 2016-06-22
EP2526967A1 (en) 2012-11-28
PL2167128T3 (pl) 2013-03-29
HK1143523A1 (en) 2011-01-07
US20100254977A1 (en) 2010-10-07
ES2395799T3 (es) 2013-02-15
SI2167128T1 (sl) 2013-01-31
EP2167128A2 (en) 2010-03-31
BRPI0815567A2 (pt) 2015-02-18
JP5341889B2 (ja) 2013-11-13
EA019485B1 (ru) 2014-04-30
CA2693863A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
BRPI0815567B8 (pt) anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica
ES2683847T3 (es) Inmunoglobulina citotóxica
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
AR073538A1 (es) Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
CL2017003351A1 (es) Anticuerpo anti receptor de transferrina humana que pasan a través de la barrera hematoencefálica.
PA8847001A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
GEP20146207B (en) ANTI-cMET ANTOBODY
GT201700102A (es) Conjugados de anticuerpo-fármaco
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
GT201300149A (es) Proteinas de union al tnf-a
AR076195A1 (es) Anticuerpos biespecificos anti-erbb-1/anti-c-met
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
PE20221007A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
EA201270769A1 (ru) Антитела к cgrp
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
CO6290705A2 (es) Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF